Fig. 3

Anti-CTLA-4 antibody- and DSS-induced inflammation drive gut-homing T cell extravasation from the blood. a The experimental design for the whole process. WT mice were treated with anti-CTLA-4 mAb or isotype control antibody every 3 days and given 1.5% DSS beginning on day 15 and 2.5% DSS beginning on day 36, each time lasts 4 days and then changed back to water. b Percent of initial weight of mice receiving an IgG isotype control (Iso Ctrl) or anti-CTLA-4 mAb (upper profile). The dynamic change in blood β7⁺CD44⁺CD4⁺ T cells is shown as the fold change in β7⁺CD44⁺ cells between the anti-CTLA-4 antibody-treated group and the IgG-treated group (lower profiles). There were 5 mice in each group. The data are shown as the mean and SEM determined by two-way ANOVA with Sidak’s correction for multiple comparisons, **P < 0.01. c The histological score of mice receiving the IgG isotype control (Iso Ctrl) or the anti-CTLA-4 mAb. Colon samples were collected at day 47. d Concentrations of KC and IL-6 in the serum of mice receiving the IgG isotype control (Iso Ctrl) or the anti-CTLA-4 mAb (day 47). e Summary of the blood CD4⁺ T cell numbers in the mice on day 47. n = 5 per group, data represent mean ± SEM. For all graphs: *P < 0.05 and **P < 0.01